UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________________________

FORM 6-K

__________________________________

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

For the quarterly period ended ~~August 31~~September 30, 2025

Commission File Number 001-38332

__________________________________

QIAGEN N.V.

(Translation of registrant’s name into English)

__________________________________

Hulsterweg 82

5912 PL Venlo

The Netherlands

(Address of principal executive office)

__________________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ý Form 40-F o

Table of Contents

QIAGEN N.V.

Form 6-K

TABLE OF CONTENTS



Item			Page
Other Information			3
Signatures			4
Exhibit Index			5

Table of Contents

OTHER INFORMATION

On ~~August~~November 284, 2025, QIAGEN N.V. (NYSE: QGEN; Frankfurt, Prime Standard: QIA) issued:

•a press release announcing aits ~~proposed~~unaudited ~~offering~~financial ofresults ~~US$750.0~~for ~~million of senior, unsecured net share settled convertible bonds in reliance on Regulation S under~~ the ~~Securities~~third ~~Act~~quarter ofended ~~1933~~September 30, ~~as amended~~2025. The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

•a press release announcing ~~the~~it ~~final~~has ~~terms~~entered ofinto ~~the~~a ~~previously~~definitive ~~announced~~agreement ~~offering~~to offully ~~new~~acquire ~~senior,~~Parse ~~unsecured net share settled convertible bonds~~Biosciences. The press release is furnished herewith as Exhibit 99.2 and is incorporated by reference herein.

•a press release announcing a plan to return up to approximately $500 million to shareholders through a synthetic share repurchase. The press release is furnished herewith as Exhibit 99.3 and is incorporated by reference herein.

•a press release announcing that Thierry Bernard will step down as Chief Executive Officer and Managing Director. The press release is furnished herewith as Exhibit 99.4 and is incorporated by reference herein.

Statement Regarding the use of Non-GAAP and Constant Currency Financial Measures

QIAGEN has regularly reported adjusted results, which are considered non-GAAP financial measures, to give additional insight into our financial performance as a supplement to understand, manage, and evaluate our business results and make operating decisions. We also use the adjusted results when comparing to our historical operating results, which have consistently been presented on an adjusted basis.

Adjusted results should be considered in addition to the reported results prepared in accordance with U.S. generally accepted accounting principles, but should not be considered as a substitute. Reconciliations of reported results to adjusted results are included in the tables accompanying the press release. We believe certain items should be excluded from adjusted results when they are outside of our ongoing core operations, vary significantly from period to period, or affect the comparability of results with the Company’s competitors and our own prior periods.

The non-GAAP financial measures used in this press release are non-GAAP gross profit, operating income, pre-tax income, net income, tax rate and diluted earnings per share. These adjusted results exclude costs related to business integration, acquisition and restructuring related items, long-lived asset impairments, amortization of acquired intangible assets, non-cash interest expense charges as well as other special income and expense items. Management views these costs as not indicative of the profitability or cash flows of our ongoing or future operations and therefore considers the adjusted results as a supplement, and to be viewed in conjunction with, the reported GAAP results.

We use a measure of free cash flow to estimate the cash flow remaining after purchases of property, plant and equipment as required to maintain or expand our business. This measure provides us with supplemental information to assess our liquidity needs. We calculate free cash flow as net cash from operating activities less purchases of property, plant and equipment.

We also consider results on a constant currency basis. Our functional currency is the U.S. dollar and our subsidiaries’ functional currencies are the local currency of the respective countries in which they are headquartered. A significant portion of our revenues and expenses is denominated in euros and currencies other than the United States dollar. Management believes that analysis of constant currency period-over-period changes is useful because changes in exchange rates can affect the growth rate of net sales and expenses, potentially to a significant degree. Constant currency figures are calculated by translating the local currency actual results in the current period using the average exchange rates from the previous year’s respective period instead of the current period.

We use non-GAAP and constant currency financial measures internally in our planning, forecasting and reporting, as well as to measure and compensate our employees. We do not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



			QIAGEN N.V.

			By:			/s/ Roland Sackers
						Roland Sackers
						Chief Financial Officer

Date: ~~August~~November 295, 2025

Table of Contents

EXHIBIT INDEX

ExhibitNo.						Exhibit
99.1						Press Release dated ~~August~~November 284, 2025
99.2						Press Release dated ~~August~~November 284, 2025
99.3						Press Release dated November 4, 2025
99.4						Press Release dated November 4, 2025

Filing Compare · QIAGEN N.V.